DDInter895 DDInter1376
Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Hydroxyzine {u} (Compound) resembles {v} (Compound) Anileridine
Hydroxyzine {u} (Compound) resembles {v} (Compound) Quetiapine
Hydroxyzine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyclizine
Hydroxyzine {u} (Compound) binds {v} (Gene) HRH1
Hydroxyzine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine Receptor Antagonists
Hydroxyzine {u} (Compound) causes {v} (Side Effect) Drowsiness
Hydroxyzine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Hydroxyzine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Hydroxyzine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Terfenadine
Hydroxyzine {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Hydroxyzine (Compound) resembles Anileridine (Compound)
Hydroxyzine (Compound) resembles Quetiapine (Compound)
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Hydroxyzine (Compound) binds HRH1 (Gene)
Hydroxyzine (Compound) is included by Histamine Receptor Antagonists (Pharmacologic Class)
Hydroxyzine (Compound) causes Drowsiness (Side Effect)
Hydroxyzine may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Hydroxyzine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine
Hydroxyzine may lead to a major life threatening interaction when taken with Macimorelin